The relationship of neutrophil/lymphocyte ratio (NLR) to prognosis of HER2-positive breast cancer (BC) is not well studied. We aimed to assess the prognostic role of NLR in HER2-positive BC patients treated with or without trastuzumab. The clinical data of 843 HER2-positive BC patients from July 2013 to July 2018 were collected. The difference among variables was calculated by chi-square test. The associations between clinicopathological factors, NLR and disease-free survival (DFS) were analyzed by univariate and multivariate analyses. Patients were divided into three groups. In group 1 containing 255 patients without trastuzumab treatment, pretreatment NLR showed no predictive value. Patients with trastuzumab treatment were divided into two groups on equal, according to pretreatment NLR values, low NLR (group 2) and high NLR (group 3). Patients in group 2 showed significantly higher 3-year DFS rate than patients in group 1 and group 3 (95.3% vs. 91.6% vs. 90.5%, respectively, P = 0.011); patients in the group 1 and group 3 had a similar 3-year DFS outcome. Multivariate analysis showed high pretreatment NLR was significantly associated with shorter DFS (HR = 2.917, 95% CI = 1.055–8.062, P = 0.039) in HER2-positive BC patients treated with trastuzumab. Among HER2-positive trastuzumab-treated BC patients, low pretreatment NLR value was associated with better DFS, and it might help to differentiate potential beneficiaries of trastuzumab treatment.

中文翻译：

---

曲妥珠单抗治疗中性粒细胞/淋巴细胞比例在HER2阳性乳腺癌预后和潜在受益者分化中的作用

中性粒细胞/淋巴细胞比（NLR）与HER2阳性乳腺癌（BC）预后的关系尚未得到很好的研究。我们旨在评估NLR在接受或不接受曲妥珠单抗治疗的HER2阳性BC患者中的预后作用。收集2013年7月至2018年7月843例HER2阳性BC患者的临床数据。通过卡方检验计算变量之间的差异。通过单因素和多因素分析对临床病理因素，NLR和无病生存期（DFS）之间的关联进行了分析。患者分为三组。在包含255名未经曲妥珠单抗治疗的患者的第1组中，治疗前的NLR没有显示预测价值。根据治疗前的NLR值，曲妥珠单抗治疗的患者分为两组，即低NLR（第2组）和高NLR（第3组）。第2组患者的3年DFS率明显高于第1组和第3组患者（分别为95.3％对91.6％对90.5％，P = 0.011）；第1组和第3组中的患者具有相似的3年DFS结果。多变量分析显示，接受曲妥珠单抗治疗的HER2阳性BC患者，较高的治疗前NLR与较短的DFS显着相关（HR = 2.917，95％CI = 1.055–8.062，P = 0.039）。在接受HER2阳性曲妥珠单抗治疗的BC患者中，较低的治疗前NLR值与更好的DFS相关，这可能有助于区分曲妥珠单抗治疗的潜在受益者。多变量分析显示，接受曲妥珠单抗治疗的HER2阳性BC患者，较高的治疗前NLR与较短的DFS显着相关（HR = 2.917，95％CI = 1.055–8.062，P = 0.039）。在接受HER2阳性曲妥珠单抗治疗的BC患者中，较低的治疗前NLR值与更好的DFS相关，这可能有助于区分曲妥珠单抗治疗的潜在受益者。多变量分析显示，接受曲妥珠单抗治疗的HER2阳性BC患者，较高的治疗前NLR与较短的DFS显着相关（HR = 2.917，95％CI = 1.055–8.062，P = 0.039）。在接受HER2阳性曲妥珠单抗治疗的BC患者中，较低的治疗前NLR值与更好的DFS相关，这可能有助于区分曲妥珠单抗治疗的潜在受益者。